ArticleJournal of translational medicine2026
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a major risk factor for chronic kidney disease (CKD), contributing to kidney dysfunction through metabolic alterations and chronic inflammation. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown significant efficacy in weight loss and metabolic control, yet real-world data on its impact on kidney function are lacking. This study aimed to evaluate the impact of three months of tirzepatide treatment on kidney function and to identify the clinical predictors of changes in estimated glomerular filtration rate (eGFR) in adults with obesity in a real-world outpatient setting.
methodsIn this retrospective real-world study, 36 adults with overweight (BMI ≥ 27.0 kg/m²) with at least one weight-related comorbidity and patients with obesity (BMI ≥ 30.0 kg/m²) undergoing treatment with tirzepatide were included. Participants received weekly tirzepatide (2.5-5 mg) for three months. Anthropometric measurements, metabolic markers (fasting glucose, insulin, HOMA-IR, and HbA1c), inflammatory status (hs-CRP), and kidney parameters (serum creatinine and eGFR via CKD-EPI) were assessed at baseline and after 3 months of treatment.
resultsAfter 3 months, serum creatinine decreased significantly (p < 0.001), and accordingly, eGFR increased after treatment (p < 0.001). In addition, significant reductions were observed in body weight (p < 0.001), BMI (p < 0.001), and waist circumference (p < 0.001). A significant decrease was observed in fasting plasma glucose (p < 0.001), HbA1c (p = 0.002), and insulin (p < 0.001) and, accordingly, in HOMA-IR (p < 0.001). Inflammatory status also improved significantly, with hs-CRP levels decreasing from baseline after 3 months of treatment with tirzepatide (p < 0.001). Correlation analysis demonstrated that ΔeGFR was inversely associated with Δweight loss (p = 0.008), ΔBMI (p = 0.007), and Δ fasting insulin (p = 0.011), while it showed a positive correlation with fasting plasma glucose (p < 0.001); a borderline negative association was also observed with ΔHOMA-IR (p = 0.053). Multiple regression analysis identified ΔBMI as the main independent predictor of ΔeGFR (p = 0.007), explaining 19.4% of the variance.
conclusionsIn a real-world setting, tirzepatide treatment was associated with improvements in kidney function alongside marked weight loss and metabolic improvements in individuals with obesity. The main driver of improvement in eGFR was primarily weight loss along with the improvement of insulin resistance, thus suggesting tirzepatide as a tool for the treatment of obesity-related kidney dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.